By the same authors

From the same journal

From the same journal

Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program

Research output: Contribution to journalArticlepeer-review

Standard

Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program. / Taurozzi, Alberto J; Beekharry, Ramprakash; Wantoch, Michelle; Labarthe, Marie-Christine; Walker, Hannah F.; Seed, Robert I; Simms, Matthew S; Rodrigues, Greta; Bradford, James; van der Horst, Geertje; van der Pluijm, Gabri; Collins, Anne T.

In: PLoS ONE, Vol. 12, No. 11, 16.11.2017, p. e0188228.

Research output: Contribution to journalArticlepeer-review

Harvard

Taurozzi, AJ, Beekharry, R, Wantoch, M, Labarthe, M-C, Walker, HF, Seed, RI, Simms, MS, Rodrigues, G, Bradford, J, van der Horst, G, van der Pluijm, G & Collins, AT 2017, 'Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program', PLoS ONE, vol. 12, no. 11, pp. e0188228. https://doi.org/10.1371/journal.pone.0188228

APA

Taurozzi, A. J., Beekharry, R., Wantoch, M., Labarthe, M-C., Walker, H. F., Seed, R. I., Simms, M. S., Rodrigues, G., Bradford, J., van der Horst, G., van der Pluijm, G., & Collins, A. T. (2017). Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program. PLoS ONE, 12(11), e0188228. https://doi.org/10.1371/journal.pone.0188228

Vancouver

Taurozzi AJ, Beekharry R, Wantoch M, Labarthe M-C, Walker HF, Seed RI et al. Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program. PLoS ONE. 2017 Nov 16;12(11):e0188228. https://doi.org/10.1371/journal.pone.0188228

Author

Taurozzi, Alberto J ; Beekharry, Ramprakash ; Wantoch, Michelle ; Labarthe, Marie-Christine ; Walker, Hannah F. ; Seed, Robert I ; Simms, Matthew S ; Rodrigues, Greta ; Bradford, James ; van der Horst, Geertje ; van der Pluijm, Gabri ; Collins, Anne T. / Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program. In: PLoS ONE. 2017 ; Vol. 12, No. 11. pp. e0188228.

Bibtex - Download

@article{0b1bd48ce9f84e8c9d4ff3794632f179,
title = "Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program",
abstract = "Prostate cancer research is hampered by the lack of in vivo preclinical models that accurately reflect patient tumour biology and the clinical heterogeneity of human prostate cancer. To overcome these limitations we propagated and characterised a new collection of patient-derived prostate cancer xenografts. Tumour fragments from 147 unsupervised, surgical prostate samples were implanted subcutaneously into immunodeficient Rag2-/-γC-/- mice within 24 hours of surgery. Histologic and molecular characterisation of xenografts was compared with patient characteristics, including androgen-deprivation therapy, and exome sequencing. Xenografts were established from 47 of 147 (32%) implanted primary prostate cancers. Only 14% passaged successfully resulting in 20 stable lines; derived from 20 independent patient samples. Surprisingly, only three of the 20 lines (15%) were confirmed as prostate cancer; one line comprised of mouse stroma, and 16 were verified as human donor-derived lymphoid neoplasms. PCR for Epstein-Barr Virus (EBV) nuclear antigen, together with exome sequencing revealed that the lymphomas were exclusively EBV-associated. Genomic analysis determined that 14 of the 16 EBV+ lines had unique monoclonal or oligoclonal immunoglobulin heavy chain gene rearrangements, confirming their B-cell origin. We conclude that the generation of xenografts from tumour fragments can commonly result in B-cell lymphoma from patients carrying latent EBV. We recommend routine screening, of primary outgrowths, for latent EBV to avoid this phenomenon.",
keywords = "Journal Article",
author = "Taurozzi, {Alberto J} and Ramprakash Beekharry and Michelle Wantoch and Marie-Christine Labarthe and Walker, {Hannah F.} and Seed, {Robert I} and Simms, {Matthew S} and Greta Rodrigues and James Bradford and {van der Horst}, Geertje and {van der Pluijm}, Gabri and Collins, {Anne T}",
note = "{\textcopyright} 2017 Taurozzi et al.",
year = "2017",
month = nov,
day = "16",
doi = "10.1371/journal.pone.0188228",
language = "English",
volume = "12",
pages = "e0188228",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program

AU - Taurozzi, Alberto J

AU - Beekharry, Ramprakash

AU - Wantoch, Michelle

AU - Labarthe, Marie-Christine

AU - Walker, Hannah F.

AU - Seed, Robert I

AU - Simms, Matthew S

AU - Rodrigues, Greta

AU - Bradford, James

AU - van der Horst, Geertje

AU - van der Pluijm, Gabri

AU - Collins, Anne T

N1 - © 2017 Taurozzi et al.

PY - 2017/11/16

Y1 - 2017/11/16

N2 - Prostate cancer research is hampered by the lack of in vivo preclinical models that accurately reflect patient tumour biology and the clinical heterogeneity of human prostate cancer. To overcome these limitations we propagated and characterised a new collection of patient-derived prostate cancer xenografts. Tumour fragments from 147 unsupervised, surgical prostate samples were implanted subcutaneously into immunodeficient Rag2-/-γC-/- mice within 24 hours of surgery. Histologic and molecular characterisation of xenografts was compared with patient characteristics, including androgen-deprivation therapy, and exome sequencing. Xenografts were established from 47 of 147 (32%) implanted primary prostate cancers. Only 14% passaged successfully resulting in 20 stable lines; derived from 20 independent patient samples. Surprisingly, only three of the 20 lines (15%) were confirmed as prostate cancer; one line comprised of mouse stroma, and 16 were verified as human donor-derived lymphoid neoplasms. PCR for Epstein-Barr Virus (EBV) nuclear antigen, together with exome sequencing revealed that the lymphomas were exclusively EBV-associated. Genomic analysis determined that 14 of the 16 EBV+ lines had unique monoclonal or oligoclonal immunoglobulin heavy chain gene rearrangements, confirming their B-cell origin. We conclude that the generation of xenografts from tumour fragments can commonly result in B-cell lymphoma from patients carrying latent EBV. We recommend routine screening, of primary outgrowths, for latent EBV to avoid this phenomenon.

AB - Prostate cancer research is hampered by the lack of in vivo preclinical models that accurately reflect patient tumour biology and the clinical heterogeneity of human prostate cancer. To overcome these limitations we propagated and characterised a new collection of patient-derived prostate cancer xenografts. Tumour fragments from 147 unsupervised, surgical prostate samples were implanted subcutaneously into immunodeficient Rag2-/-γC-/- mice within 24 hours of surgery. Histologic and molecular characterisation of xenografts was compared with patient characteristics, including androgen-deprivation therapy, and exome sequencing. Xenografts were established from 47 of 147 (32%) implanted primary prostate cancers. Only 14% passaged successfully resulting in 20 stable lines; derived from 20 independent patient samples. Surprisingly, only three of the 20 lines (15%) were confirmed as prostate cancer; one line comprised of mouse stroma, and 16 were verified as human donor-derived lymphoid neoplasms. PCR for Epstein-Barr Virus (EBV) nuclear antigen, together with exome sequencing revealed that the lymphomas were exclusively EBV-associated. Genomic analysis determined that 14 of the 16 EBV+ lines had unique monoclonal or oligoclonal immunoglobulin heavy chain gene rearrangements, confirming their B-cell origin. We conclude that the generation of xenografts from tumour fragments can commonly result in B-cell lymphoma from patients carrying latent EBV. We recommend routine screening, of primary outgrowths, for latent EBV to avoid this phenomenon.

KW - Journal Article

U2 - 10.1371/journal.pone.0188228

DO - 10.1371/journal.pone.0188228

M3 - Article

C2 - 29145505

VL - 12

SP - e0188228

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 11

ER -